Moctanin
Executive Summary
Orphan gallstone dissolver is marketed by Ethitek, not Ascot Pharamaceuticals ("The Pink Sheet" Oct. 10, T&G-10). Ethitek was formed in April 1986 after Baxter Travenol purchased all the assets, with the exception of Moctanin, of Ascot Hospital Pharmaceuticals. Moctanin (monoctanoin) is Ethitek's only product; however, the firm is pursuing expanded indications and is currently in clinicals for use of Moctanin as a dissolution agent for stones in the gallbladder.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.